Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.14368 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and Safety of Risankizumab for Psoriasis in a Liver Transplant Patient With Recurrent Metastatic Hepatocellular Carcinoma.
Cureus
August 2025
Dermatology, Hôpital Privé Francheville, Perigueux, FRA.
Risankizumab (RZB) is a humanized monoclonal antibody that selectively targets interleukin-23 (IL-23). It has proven particularly effective in treating psoriasis, a common chronic inflammatory skin disease. However, its use remains poorly documented in certain populations, including patients with a history of solid organ transplantation or recent/active malignancy.
View Article and Find Full Text PDFResearch Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
Aliment Pharmacol Ther
July 2025
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.
View Article and Find Full Text PDFRisankizumab differentially modulates circulating T-cell populations in psoriasis according to autoreactivity status.
J Dermatol Sci
August 2025
Department of Biomedical Sciences Humanitas University, Milan, Italy; Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy. Electronic address:
Background: In a recent paper, our group described that the presence of double autoreactivity to both LL37 and ADAMTSL5 autoantigens in psoriatic patients decreased the clinical responses to risankizumab, but how this influences the changes in the peripheral inflammatory T-cell populations is still unknown.
Objective: This study aims to evaluate how risankizumab modulates the circulating inflammatory T-cell populations in psoriatic patients and, specifically, in autoreactive subjects.
Methods: The presence of LL37- and ADAMTSL5-reactive circulating T-cells was assessed in a cohort of 142 psoriatic patients, and 87 demonstrated autoreactivity at baseline.
Global consensus statement on the management of pregnancy in inflammatory bowel disease.
Gut
August 2025
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Background & Aims: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes.
View Article and Find Full Text PDF